Hydroxychloroquine + Azithromycin therapy at a higher dose improved survival

E

ExpressLane

Verified User
“We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients,” the study’s conclusion states.


Abstract
Introduction This observational study looked at 255 COVID19 patients who required invasive mechanical ventilation (IMV) during the first two months of the US pandemic. Through comprehensive, longitudinal evaluation and new consideration of all the data, we were able to better describe and understand factors affecting outcome after intubation.

Methods All vital signs, laboratory values, and medication administrations (time, date, dose, and route) were collected and organized. Further, each patient’s prior medical records, including PBM data and available ECG, were reviewed by a physician. These data were incorporated into time-series database for statistical analysis.

Results By discharge or Day 90, 78.2% of the cohort expired. The most common pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and obesity (50.4%). Age correlated with death. Comorbidities and clinical status on presentation were not predictive of outcome. Admission markers of inflammation were universally elevated (>96%). The cohort’s weight range was nearly 7-fold. Causal modeling establishes that weight-adjusted HCQ and AZM therapy improves survival by over 100%. QTc prolongation did not correlate with cumulative HCQ dose or HCQ serum levels.

Discussion This detailed approach gives us better understanding of risk factors, prognostic indicators, and outcomes of Covid patients needing IMV. Few variables were related to outcome. By considering more factors and using new methods, we found that when increased doses of co-administered HCQ and AZM were associated with >100% increase in survival. Comparison of absolute with weight-adjusted cumulative doses proves administration ≥80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring Covid patients by over 100%. According to our data, HCQ is not associated with prolongation. Studies, which reported QTc prolongation secondary to HCQ, need to be re-evaluated more stringently and with controls.

The weight ranges of Covid patient cohorts are substantially greater than those of most antibiotic RCTs. Future clinical trials need to consider the weight variance of hospitalized Covid patients and need to study therapeutics more thoughtfully.



https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
============================================================================
Trump was right again. To bad people had to die because the Democrats could not stand for Trump be correct.
 
ExpressLane said:
“We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients,” the study’s conclusion states.


Abstract
Introduction This observational study looked at 255 COVID19 patients who required invasive mechanical ventilation (IMV) during the first two months of the US pandemic. Through comprehensive, longitudinal evaluation and new consideration of all the data, we were able to better describe and understand factors affecting outcome after intubation.

Methods All vital signs, laboratory values, and medication administrations (time, date, dose, and route) were collected and organized. Further, each patient’s prior medical records, including PBM data and available ECG, were reviewed by a physician. These data were incorporated into time-series database for statistical analysis.

Results By discharge or Day 90, 78.2% of the cohort expired. The most common pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and obesity (50.4%). Age correlated with death. Comorbidities and clinical status on presentation were not predictive of outcome. Admission markers of inflammation were universally elevated (>96%). The cohort’s weight range was nearly 7-fold. Causal modeling establishes that weight-adjusted HCQ and AZM therapy improves survival by over 100%. QTc prolongation did not correlate with cumulative HCQ dose or HCQ serum levels.

Discussion This detailed approach gives us better understanding of risk factors, prognostic indicators, and outcomes of Covid patients needing IMV. Few variables were related to outcome. By considering more factors and using new methods, we found that when increased doses of co-administered HCQ and AZM were associated with >100% increase in survival. Comparison of absolute with weight-adjusted cumulative doses proves administration ≥80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring Covid patients by over 100%. According to our data, HCQ is not associated with prolongation. Studies, which reported QTc prolongation secondary to HCQ, need to be re-evaluated more stringently and with controls.

The weight ranges of Covid patient cohorts are substantially greater than those of most antibiotic RCTs. Future clinical trials need to consider the weight variance of hospitalized Covid patients and need to study therapeutics more thoughtfully.



https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
============================================================================
Trump was right again. To bad people had to die because the Democrats could not stand for Trump be correct.
Click to expand...

The more you try to defend your ass snot guy the more you embarrass yourself
 
Here are the results of an Indian study just published. I doubt that Fauci will have any reputation intact after this and his involvement in the Wuhan disaster. So where are the JPP 'experts' like Nutberg, Madwitch, McMoonshi'ite, Hoosier Daddy, Arsecheese, Trumpet, McSlobber, Katzshit et al now?



Remember Donald Trump-touted hydroxychloroquine? Study in India backs it as Covid-19 cure

Hydroxychloroquine, the malaria drug touted as a magical Covid-19 cure by former US President Donald Trump last year, has been found effective in a prophylactic study published in the Journal of The Association of Physicians of India.

Prabhash K Dutta New Delhi
June 7, 2021
UPDATED: June 8, 2021 07:52 IST

Hydroxychloroquine, the malaria drug touted as a magical Covid-19 cure by former US President Donald Trump last year, has been found effective in a prophylactic study published in the Journal of The Association of Physicians of India (JAPI) last week. The study showed that hydroxychloroquine, popularly known as HCQ, could prevent SARS-CoV-2 infection in varying degrees depending on its dosing regimen. The highest prevention rate of 72 per cent was found among those given hydroxychloroquine over six weeks or a longer duration. The study said, “When adjusted for other risk factors, HCQ dose as per government recommendations, 2-3, 4-5, 6 or more weeks reduced the probability of Covid positivity by 34 per cent, 48 per cent and 72 per cent.”

The study was conducted May-September last year when HCQ was still part of the Union health ministry’s recommendation in treatment protocol for Covid-19. The study began against the backdrop of contesting claims made by authorities and experts including Donald Trump and his advisor Dr Anthony Fauci, the US’s top infectious disease expert.

In March 2020, Donald Trump declared that hydroxichloroquine was a “game changer” drug in the fight against Covid-19. Dr Fauci dismissed the claim citing lack of study and evidence. Despite Fauci’s counter-positioning, Trump continued to be vocal about taking HCQ as prophylactic drug.

Incidentally, the Union health ministry on June 6 dropped hydroxychloroquine from Covid-19 treatment protocol. In its nine-page guidelines released on Sunday (June 6) by the directorate of health services, hydroxychloroquine, ivermectin and favipiravir find no mention.

The government’s decision came on the back of criticism by experts who pointed out a lack of study-based evidence to recommend hydroxychloroquine in Covid-19 cases. The government’s revised guidelines, however, contradicts the recommendations made by the Indian Council of Medical Research as released on May 17. The ICMR guidelines prescribed the use of hydroxychloroquine in mild cases of Covid-19. The authors of this prophylactic (relating to prevention of a disease) study said that this “is the largest multicenter study on HCQ prophylaxis on HCWs (healthcare workers), covering over 12,000 HCWs at the risk of Covid-19”.

The study was conducted in May-September last year across 44 hospitals in 17 states involving hundreds of doctors, who received doses of hydroxychloroquine. One of the co-authors of the study, Dr Raj Kamal Choudhry said, “In the 1985-86 edition of Harrison's Principles of Internal Medicine [a highly recommended book for students studying medicine in medical colleges], Dr Fauci wrote that HCQ worked an anti-viral agent despite being an anti-malarial drug. There was no Covid-19 back then. HCQ’s anti-viral properties were known.”

Dr Raj Kamal Choudhry, who was the nodal officer for the prophylaxis study of HCQ in Bihar’s Bhagalpur medical college, said, “We had given about 2,700 doctors and paramedical staff, laundry and kitchen people the prophylaxis of HCQs in the dose of HCQs 400 mg 1×2 for first day then 1 tab daily for 4 days. We did not give to those who had palpitations and had QT prolongation [a measure of heart ailment]. Those who took this drug did not have Covid excepting 5 and 6. The effect was tremendous. Later, we gave this drug to all who had mild cases. Only those patients who were in ICU were not given.”

“Of 2,700 people who were given HCQs, 700 were doctors. Only five or six got infected with SARS-CoV-2 in Bhagalpur but none developed serious complications, and nobody died of Covid-19,” Dr Raj Kamal Choudhry told Indiatoday.in.

Incidentally, Donald Trump, who tested positive for Covid-19 in October, recovered fast from the coronavirus infection without showing any serious complication. In their conclusion, the researchers said, “HCQ is effective in reducing risk of Covid-19, at 800 mg loading and 400 mg weekly dose with more than 2 weeks dosing.”

They said the HCQ was “well tolerated” among the participants. As policy implications of the study, the authors said, “Vaccine has its own limitations, and therefore an alternative strategy of prophylaxis such as HCQ is important, especially in low resource settings.”

The outcome of the study is significant given that India is facing acute shortage of vaccine doses, and it is still likely to take a few months before availability of vaccines improves in the country. However, the decision on who could be advised to go for HCQ prophylaxis would require a relook by the Union health ministry and the ICMR.
Click to expand...

https://www.indiatoday.in/coronavir...dia-backs-as-covid-19-cure-1811892-2021-06-07
 
Last edited:
katzgar said:
Nope it doesn't say that you're a liar
Click to expand...

I don't hold that these nuts actually mean to lie- with the exception of the Brit maggot. You can observe all of them flocking to the same superstitious, debunked, contrary, inflammatory and otherwise primitive beliefs. The underpinning motives seem to me to be pathological fear of change along with a deep-rooted antagonism to anything which challenges Evangelical dogma or is likely to rock their capitalist ...er.....principals.

It follows that a large percentage of America's population is mentally unbalanced.
 
Last edited:
moon said:
I don't hold that these nuts actually mean to lie- with the exception of the Brit maggot. You can observe all of them flocking to the same superstitious, debunked, contrary, inflammatory and otherwise primitive beliefs. The underpinning motives seem to me to be pathological fear of change along with a deep-rooted antagonism to anything which challenges Evangelical dogma or is likely to rock their capitalist ...er.....principals.

It follows that a large percentage of America's population are mentally unbalanced.
Click to expand...

It seems to me that chronic TDS overrides any rational analysis of HCQ by JPP 'virologists', McMoonshi'ite being one of the worst along with Katzshit and Madwitch.
 
Almost certainly tens of thousands of Americans died who only died because they did not have the best treatments we had available. Bret makes a great point that we should be using ivermectin for example, that there is no excuse for us having not been using it for a long time now .

 
Primavera said:
It seems to me that chronic TDS overrides any rational analysis of HCQ by JPP 'virologists', McMoonshi'ite being one of the worst along with Katzshit and Madwitch.
Click to expand...

Trump hate rots brains.

Yes, America really does suck this badly now in spite of all of the Happy Horseshit conservatives serve up.
 
moon said:
I don't hold that these nuts actually mean to lie- with the exception of the Brit maggot. You can observe all of them flocking to the same superstitious, debunked, contrary, inflammatory and otherwise primitive beliefs. The underpinning motives seem to me to be pathological fear of change along with a deep-rooted antagonism to anything which challenges Evangelical dogma or is likely to rock their capitalist ...er.....principals.

It follows that a large percentage of America's population is mentally unbalanced.
Click to expand...

You can't spell principles correctly, shi'ite for brains.
 
moon said:
I don't hold that these nuts actually mean to lie- with the exception of the Brit maggot. You can observe all of them flocking to the same superstitious, debunked, contrary, inflammatory and otherwise primitive beliefs. The underpinning motives seem to me to be pathological fear of change along with a deep-rooted antagonism to anything which challenges Evangelical dogma or is likely to rock their capitalist ...er.....principals.

It follows that a large percentage of America's population is mentally unbalanced.
Click to expand...

studies show they are low IQ and have cognitive issues
 
ExpressLane said:
“We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients,” the study’s conclusion states.


Abstract
Introduction This observational study looked at 255 COVID19 patients who required invasive mechanical ventilation (IMV) during the first two months of the US pandemic. Through comprehensive, longitudinal evaluation and new consideration of all the data, we were able to better describe and understand factors affecting outcome after intubation.

Methods All vital signs, laboratory values, and medication administrations (time, date, dose, and route) were collected and organized. Further, each patient’s prior medical records, including PBM data and available ECG, were reviewed by a physician. These data were incorporated into time-series database for statistical analysis.

Results By discharge or Day 90, 78.2% of the cohort expired. The most common pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and obesity (50.4%). Age correlated with death. Comorbidities and clinical status on presentation were not predictive of outcome. Admission markers of inflammation were universally elevated (>96%). The cohort’s weight range was nearly 7-fold. Causal modeling establishes that weight-adjusted HCQ and AZM therapy improves survival by over 100%. QTc prolongation did not correlate with cumulative HCQ dose or HCQ serum levels.

Discussion This detailed approach gives us better understanding of risk factors, prognostic indicators, and outcomes of Covid patients needing IMV. Few variables were related to outcome. By considering more factors and using new methods, we found that when increased doses of co-administered HCQ and AZM were associated with >100% increase in survival. Comparison of absolute with weight-adjusted cumulative doses proves administration ≥80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring Covid patients by over 100%. According to our data, HCQ is not associated with prolongation. Studies, which reported QTc prolongation secondary to HCQ, need to be re-evaluated more stringently and with controls.

The weight ranges of Covid patient cohorts are substantially greater than those of most antibiotic RCTs. Future clinical trials need to consider the weight variance of hospitalized Covid patients and need to study therapeutics more thoughtfully.



https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
============================================================================
Trump was right again. To bad people had to die because the Democrats could not stand for Trump be correct.
Click to expand...

medRxiv (pronounced "med-archive") is an Internet site distributing unpublished eprints about health sciences.[1][2][3][4] It distributes complete but unpublished manuscripts in the areas of medicine, clinical research, and related health sciences without charge to the reader. Such manuscripts have yet to undergo peer review and the site notes that preliminary status and that the manuscripts should not be considered for clinical application, nor relied upon for news reporting as established information.[5] Medical photographs cannot be included in preprints on medRxiv, since the editorial team does not have the resources of a journal to do thorough checks of patient consent.

https://en.wikipedia.org/wiki/MedRxiv
 
You must log in or register to reply here.
Back
Top